Edwards Lifesciences Corp (EW)

Medtronic PLC

In Transcatheter Aortic Valve Replacement, our primary competitors include this company, Abbott Laboratories ("Abbott"), and Boston Scientific Corporation. In Surgical Structural Heart, our primary competitors include this company, Abbott, and Artivion, Inc (formerly CryoLife). "

Abbott Laboratories

In Transcatheter Aortic Valve Replacement, our primary competitors include Medtronic PLC, this company, and Boston Scientific Corporation. In Transcatheter Mitral and Tricuspid Therapies, our primary competitor is this company, and there are a considerable number of large and small companies with development efforts in these fields. In Surgical Structural Heart, our primary competitors include Medtronic PLC, this company, and Artivion, Inc (formerly CryoLife). "

Boston Scientific Corp

In Transcatheter Aortic Valve Replacement, our primary competitors include Medtronic PLC, Abbott Laboratories ("Abbott"), and this company. "

Artivion Inc

In Surgical Structural Heart, our primary competitors include Medtronic PLC, Abbott, and this company (formerly CryoLife). "

ICU Medical Inc

In Critical Care, we compete primarily with a variety of companies in specific product lines including this company, PULSION Medical Systems SE, a subsidiary of Getinge AB, Cheetah Medical, Inc., a subsidiary of Baxter International, and LiDCO Group PLC, a subsidiary of Masimo Corporation. "

PULSION Medical Systems SE

In Critical Care, we compete primarily with a variety of companies in specific product lines including ICU Medical, Inc., this company, a subsidiary of Getinge AB, Cheetah Medical, Inc., a subsidiary of Baxter International, and LiDCO Group PLC, a subsidiary of Masimo Corporation. "

Cheetah Medical, Inc.

In Critical Care, we compete primarily with a variety of companies in specific product lines including ICU Medical, Inc., PULSION Medical Systems SE, a subsidiary of Getinge AB, this company, a subsidiary of Baxter International, and LiDCO Group PLC, a subsidiary of Masimo Corporation. "

LiDCO Group PLC

In Critical Care, we compete primarily with a variety of companies in specific product lines including ICU Medical, Inc., PULSION Medical Systems SE, a subsidiary of Getinge AB, Cheetah Medical, Inc., a subsidiary of Baxter International, and this company, a subsidiary of Masimo Corporation. "

Innovalve Bio Medical Limited

2024

Edwards acquired Innovalve for an aggregate cash price of $300 million plus an additional $25 million contingent on a regulatory milestone. The deal, executed in July 2024 and expected to close by year‐end, strategically enhances Edwards’ transcatheter mitral and tricuspid therapies portfolio by integrating an early-stage TMVR system. " " " " "

Endotronix, Inc.

2024

Edwards acquired Endotronix, Inc. for a total consideration of $798.8 million (including cash, fair value adjustment of a previously held equity interest, and settlement of pre-existing relationships) with an additional $2.0 million milestone payment and $35.0 million placed in escrow. This strategic acquisition enables Edwards to enter the heart failure management market by leveraging Endotronix’s FDA-approved Cordella Sensor. " " " "

JC Medical, Inc.

2024

Edwards completed the acquisition of JC Medical, Inc. on July 22, 2024, for a base purchase price of $116.3 million plus up to $200 million in milestone payments, including specified allocations for goodwill and IPR&D. The acquisition supports expansion of Edwards’ TAVR portfolio to address conditions like aortic regurgitation, with part of the cash consideration held in escrow for indemnification claims. " " "

JenaValve Technology, Inc.

2024

Edwards acquired JenaValve Technology, Inc. for an aggregate cash price of $500 million with an additional $445 million contingent on achieving regulatory and sales milestones. The acquisition is strategically aimed at expanding the structural heart portfolio for aortic regurgitation, with anticipated FDA approval of the JenaValve Trilogy Heart Valve System in late 2025 and subject to closing conditions like antitrust and foreign investment approvals. " " " " "

Early-stage medical device company

2024

Edwards acquired an undisclosed early-stage medical device company developing a catheter-based system for valvular disease treatment. The transaction involved initial payments totaling $115.0 million (distributed in two installments) with potential additional payments of up to $200.0 million upon achieving sales milestones. "

Medical technology company

2023

Edwards acquired 61% of a medical technology company on February 28, 2023, in an all-cash transaction valued at $175.8 million. The acquisition, structured as a business combination with detailed asset and liability allocations (including significant goodwill and an option agreement for the remaining interest), is aimed at enhancing Edwards’ cardiovascular disease detection and management capabilities. " " "